A Study of TQ-B3525 on Tolerance and Pharmacokinetics
NCT03510767
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Lymphoma or Advanced Cancer
Interventions
DRUG:
TQ-B3525
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.